Home › Compare › SOOBF vs ABBV
SOOBF yields 11.77% · ABBV yields 3.06%● Live data
📍 SOOBF pulled ahead of the other in Year 1
Combined, SOOBF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SOOBF + ABBV for your $10,000?
Sapporo Holdings Limited engages in alcoholic beverages, foods and soft drinks, restaurants, and real estate businesses in Japan and internationally. It operates through Alcoholic Beverages, Food & Soft Drinks, and Real Estate segments. The company manufactures and sells beer, wine, other alcoholic beverages, foods, sundries, shochu, and other food products; operates restaurants and factories; and offers soft drinks, soups, and soybeans and chilled products, as well as provides consigned freight forwarding, cargo handling, warehousing, packaging, and distribution services. It also manufactures, markets, and sells beverages and food products; operates vending machines and café chain; serves tea; and manufactures and sells ice cream, miso, instant miso soup, and freeze-dried products. In addition, the company engages in the development, leasing, rental, and sale of real estate properties. As of December 31, 2021, it operated 162 restaurant outlets. The company sells its beer products under the Black label, Yebisu, GOLD STAR, SAPPORO PREMIUM BEER, ANCHOR, and Mugi to Hop brand names. Sapporo Holdings Limited was founded in 1876 and is headquartered in Tokyo, Japan.
Full SOOBF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.